Results 211 to 220 of about 1,703,142 (259)

A fatal posterior-fossa chloroma masquerading as tuberculous meningitis after peripartum BCR-ABL1 inhibitor cessation - a case report. [PDF]

Leuk Res Rep
Zutshi B, Garg S, Bharti P, Kumar A, Chakraborty A, Miglani S, Meena AK, Chahal AS, Ghosh SS.   +8 more
europepmc   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Leucine, autoimmune diseases, and circulating mediators shape the causal landscape of lymphoid malignancies. [PDF]

Front Immunol
Liang D, Ren Y, Feng Y, Li Q, Sharma A, Schmidt-Wolf IGH, Pu J.   +6 more
europepmc   +1 more source

Evasins: Biology and Therapeutic Potential of Broad‐Spectrum Chemokine Inhibitors

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
ABSTRACT Ticks are haematophagous parasites that rely on uninterrupted bloodmeals for survival and need an effective strategy to suppress the host inflammatory response. Leukocyte recruitment is a chemokine‐mediated hallmark of inflammation, which ticks counteract via anti‐chemokine proteins in their saliva named evasins.
Emilia L. Bialek, Roos Buds, Ingrid Dijkgraaf, Pedro E. Marques   +3 more
wiley   +1 more source

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL. [PDF]

Int J Hematol
Nakata Y, Hiratsuka A, Yoroidaka T, Takahashi W, Nishikawa I, Sakashita M, Yamada S, Mizumaki H, Yoshida A, Imi T, Maruyama H, Takamatsu H, Hosokawa K, Nannya Y, Ogawa S, Miyamoto T.   +15 more
europepmc   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, Volume 117, Issue 4, Page 739-749, October 2026.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Case Report: A unique case of Philadelphia chromosome-positive mixed-phenotype acute leukemia with active Epstein-Barr virus infection in a kidney transplantation recipient. [PDF]

Front Oncol
Chen M, Hu X, Feng W, Zhou.
europepmc   +1 more source

Early Acute Kidney Injury in Allogeneic Hematopoietic Cell Transplantation: Incidence, Severity, and Associated Factors in a 634‐Recipient Cohort

European Journal of Haematology, Volume 117, Issue 4, Page 981-994, October 2026.
ABSTRACT Background Acute kidney injury (AKI) is a frequent and clinically relevant complication in allogeneic hematopoietic cell transplantation (HCT) recipients, particularly during the early post‐HCT period. Although AKI has been extensively reported in long‐term follow‐up studies, data focusing on the initial hospitalization phase remain limited ...
Luiz Carlos da Costa‐Junior, Rita de Cássia Barbosa da Silva Tavares, Marina Izu, Simone Cunha Maradei, Maria Claudia Rodrigues Moreira, Marta Colares Nogueira, Décio Lerner, Fabrício Guimarães Bino, Patrícia Moriel, Teresa de Souza Fernandez, Paulo Caleb Júnior Lima Santos   +10 more
wiley   +1 more source

Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms. [PDF]

Blood Neoplasia
Adkins J, Zhao C.
europepmc   +1 more source

The spatial and multi-omic landscape of Down syndrome leukemogenesis: moving beyond cellular heterogeneity. [PDF]

Exp Hematol Oncol
Peroni E, Amato R, Bado M, Favarato M, Rosato A.   +4 more
europepmc   +1 more source